AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17824581 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with clindamycin 1%-BPO 5% topical gel plus adapalene gel 0.1%
Number of subjects: 0
Study 15145332 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (Aca)
Number of subjects: 20
Study 15145332 — intervention group
Group type: EXPERIMENTAL
Intervention: Voglibose (Vog)
Number of subjects: 20
Study 15145332 — intervention group
Group type: COMPARATOR
Intervention: Acarbose (Aca) and Voglibose (Vog)
Number of subjects: 20
Study 11210872 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 20
Study 11210872 — intervention group
Group type: COMPARATOR
Intervention: Control (no fibrin sealant)
Number of subjects: 20
Study 9780616 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine (4 mg/die)
Number of subjects: 19
Study 9780616 — intervention group
Group type: COMPARATOR
Intervention: Idroclorotiazide + amiloride (50 mg every other day)
Number of subjects: 19
Study 8155437 — intervention group
Group type: EXPERIMENTAL
Intervention: Space blanket (not less than 60% of body surface area)
Number of subjects: 68
Study 8155437 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical draping
Number of subjects: 68
Study 8155437 — intervention group
Group type: EXPERIMENTAL
Intervention: Space blanket
Number of subjects: 68
Study 3283632 — intervention group
Group type: EXPERIMENTAL
Intervention: nonselective beta‐blocker (timolol maleate 0.5%)
Number of subjects: 60
Study 3283632 — intervention group
Group type: EXPERIMENTAL
Intervention: cardioselective beta‐1‐blocking agent (betaxolol‐HCl 0.5%)
Number of subjects: 60
Study 3283632 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 31112706 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe polysaccharide (APS) 600 mg/day
Number of subjects: 40
Study 31112706 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis 600 mg/day
Number of subjects: 40
Study 31112706 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of APS (420 mg/day) and propolis (180 mg/day)
Number of subjects: 40
Study 31112706 — intervention group
Group type: COMPARATOR
Intervention: Control group (smokers without supplementation)
Number of subjects: 40
Study 28951766 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet (N = 26)
Number of subjects: 107
Study 28951766 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-Exercise (N = 28)
Number of subjects: 107
Study 28951766 — intervention group
Group type: COMPARATOR
Intervention: Control (N = 27)
Number of subjects: 107
Study 28951766 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (N = 26)
Number of subjects: 107
Study 26670970 — intervention group
Group type: EXPERIMENTAL
Intervention: HSCT (n=23)
Number of subjects: 45
Study 26670970 — intervention group
Group type: COMPARATOR
Intervention: Control (n=22)
Number of subjects: 45
Study 23656645 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (1 g daily)
Number of subjects: 12513
Study 23656645 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 12513
Study 21245085 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (21-mg nicotine transdermal patch)
Number of subjects: 40
Study 21245085 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo patch)
Number of subjects: 40
Study 18291067 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Inspection with Acetic Acid and Magnification (VIAM)
Number of subjects: 358
Study 18291067 — intervention group
Group type: COMPARATOR
Intervention: Visual Inspection with Acetic Acid (VIA)
Number of subjects: 358
Study 16600927 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucaloric low-fat, high-carbohydrate diet
Number of subjects: 22
Study 16600927 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum low-fat, high-carbohydrate diet
Number of subjects: 22
Study 12741860 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino Acid (AA)
Number of subjects: 17
Study 12741860 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 17
Study 11001674 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (GC)
Number of subjects: 405
Study 11001674 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC)
Number of subjects: 405
Study 8760987 — intervention group
Group type: EXPERIMENTAL
Intervention: Full angioscopic (ANG) vein preparation
Number of subjects: 47
Study 8760987 — intervention group
Group type: COMPARATOR
Intervention: Conventional (CON) in situ grafting
Number of subjects: 47
Study 8760987 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion angioscopy
Number of subjects: 47
Study 8760987 — intervention group
Group type: COMPARATOR
Intervention: Arteriography
Number of subjects: 47
Study 1314065 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) CY 216, 48 mg subcutaneous injection and two placebo injections per day.
Number of subjects: 341
Study 1314065 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UH), 5000 IU t.i.d.
Number of subjects: 341
Study 3882058 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (10 to 20 mg/kg/day, twice daily)
Number of subjects: 14
Study 3882058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 3882058 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 14
Study 31910891 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched GLB (McGill CHIP Healthy Weight Program)
Number of subjects: 110
Study 31910891 — intervention group
Group type: COMPARATOR
Intervention: Standard GLB
Number of subjects: 110
Study 31572293 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase
Number of subjects: 48
Study 31572293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 28420324 — intervention group
Group type: EXPERIMENTAL
Intervention: ICT-enhanced integrated care model (SPEC)
Number of subjects: 10
Study 25299401 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 56
Study 25299401 — intervention group
Group type: COMPARATOR
Intervention: Nebivolol
Number of subjects: 56
Study 24571216 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive stimulation intervention
Number of subjects: 0
Study 24571216 — intervention group
Group type: COMPARATOR
Intervention: Enhanced nutrition intervention
Number of subjects: 0
Study 22512843 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg per day orally)
Number of subjects: 296
Study 22512843 — intervention group
Group type: COMPARATOR
Intervention: Placebo (orally)
Number of subjects: 296
Study 22512843 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 296
Study 22512843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study 18635285 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine/oxaliplatin/vinorelbine combination
Number of subjects: 39
Study 16814221 — intervention group
Group type: EXPERIMENTAL
Intervention: CenteringPregnancy
Number of subjects: 98
Study 16814221 — intervention group
Group type: COMPARATOR
Intervention: Traditional prenatal care
Number of subjects: 98
Study 14522634 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% and 0.03% ointment
Number of subjects: 16000
Study 14522634 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment
Number of subjects: 16000
Study 10979901 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-12 (3-300 ng/kg)
Number of subjects: 47
Study 10979901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 10979901 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-12 (1000 ng/kg)
Number of subjects: 47
Study 8761839 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (5 days per week of supervised treadmill exercise plus stair climbing for 12 weeks)
Number of subjects: 22
Study 8761839 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise for 12 weeks)
Number of subjects: 22
Study 1564133 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication vial with a digital timepiece cap (Phase I)
Number of subjects: 70
Study 1564133 — intervention group
Group type: COMPARATOR
Intervention: Standard medication vial (Phase I control)
Number of subjects: 70
Study 1564133 — intervention group
Group type: EXPERIMENTAL
Intervention: Timepiece cap and pocket-size card (Phase II)
Number of subjects: 70
Study 1564133 — intervention group
Group type: EXPERIMENTAL
Intervention: Timepiece cap, pocket-size card, and blood pressure cuff (Phase II)
Number of subjects: 70
Study 3907314 — intervention group
Group type: EXPERIMENTAL
Intervention: Moricizine (ethmozine) 10 to 12 mg/kg/day, administered every 12 hours
Number of subjects: 10
Study 3907314 — intervention group
Group type: EXPERIMENTAL
Intervention: Moricizine (ethmozine) 10 to 12 mg/kg/day, administered every 8 hours
Number of subjects: 10
Study 3907314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3907314 — intervention group
Group type: EXPERIMENTAL
Intervention: Moricizine (ethmozine) every 12 hours
Number of subjects: 10
Study 3907314 — intervention group
Group type: EXPERIMENTAL
Intervention: Moricizine (ethmozine) every 8 hours
Number of subjects: 10
Study 31738682 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed active learning (SDL)
Number of subjects: 100
Study 31738682 — intervention group
Group type: COMPARATOR
Intervention: In-person instructor demonstration
Number of subjects: 100
Study 31738682 — intervention group
Group type: COMPARATOR
Intervention: Online module instruction
Number of subjects: 100
Study 30806952 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention (Symphony No. 40 by Mozart played via headphones) during dental care
Number of subjects: 34
Study 30806952 — intervention group
Group type: COMPARATOR
Intervention: No music intervention
Number of subjects: 34
Study 29949175 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT‐2 inhibitor in addition to routine insulin therapy
Number of subjects: 126
Study 29949175 — intervention group
Group type: COMPARATOR
Intervention: Insulin therapy only
Number of subjects: 126
Study 26038610 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual cues combined with treadmill training
Number of subjects: 23
Study 26038610 — intervention group
Group type: COMPARATOR
Intervention: Pure treadmill training
Number of subjects: 23
Study 24635550 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine abstinence during treatment (8 or 12 weeks)
Number of subjects: 434
Study 24635550 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine use measures (percent days abstinent, percent positive urines, maximum days of consecutive abstinence)
Number of subjects: 434
Study 24635550 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotomous measure of cocaine use (≥21 consecutive days of abstinence)
Number of subjects: 434
Study 22452356 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (400 mg twice daily)
Number of subjects: 265
Study 22452356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study 22452356 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 265
Study 20472995 — intervention group
Group type: EXPERIMENTAL
Intervention: PMMA‐CHDF (continuous hemodiafiltration with a cytokine‐adsorbing hemofilter)
Number of subjects: 51
Study 20472995 — intervention group
Group type: COMPARATOR
Intervention: IHD+CHF (intermittent hemodialysis without water removal for elimination of metabolites and continuous hemofiltration for fluid management)
Number of subjects: 51
Study 18095008 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (HM)
Number of subjects: 100
Study 18095008 — intervention group
Group type: COMPARATOR
Intervention: Morphine (M)
Number of subjects: 100
Study 15990269 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (received clustering strategies)
Number of subjects: 120
Study 15990269 — intervention group
Group type: COMPARATOR
Intervention: Control group (received original instructions only)
Number of subjects: 120
Study 12480803 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF with palm olein (PO)
Number of subjects: 22
Study 12480803 — intervention group
Group type: COMPARATOR
Intervention: CHF without palm olein (PO)
Number of subjects: 22
Study 12480803 — intervention group
Group type: EXPERIMENTAL
Intervention: SPF with palm olein (PO)
Number of subjects: 22
Study 12480803 — intervention group
Group type: COMPARATOR
Intervention: SPF without palm olein (PO)
Number of subjects: 22
Study 10780808 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg) + Ethanol (0.5 g/kg)
Number of subjects: 16
Study 10780808 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (100 mg) + Ethanol (1.0 g/kg)
Number of subjects: 16
Study 10780808 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg) + Pentobarbital (150 mg)
Number of subjects: 16
Study 10780808 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (100 mg) + Pentobarbital (300 mg)
Number of subjects: 16
Study 10780808 — intervention group
Group type: COMPARATOR
Intervention: Ethanol (0 g/kg)
Number of subjects: 16
Study 10780808 — intervention group
Group type: COMPARATOR
Intervention: Pentobarbital (0 mg)
Number of subjects: 16
Study 7862544 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Performance Inventory (MPI)
Number of subjects: 197
Study 1719716 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified cholera chemical vaccine (choleragen‐toxoid + O‐antigens Inaba and Ogawa)
Number of subjects: 278
Study 1719716 — intervention group
Group type: COMPARATOR
Intervention: Commercial batch of monovalent cholera vaccine (choleragen‐toxoid + O‐antigen Inaba)
Number of subjects: 278
Study 6110954 — intervention group
Group type: EXPERIMENTAL
Intervention: bendroflumethiazide
Number of subjects: 53
Study 6110954 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol
Number of subjects: 53
Study 31425383 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 26
Study 31425383 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 26
Study 30678635 — intervention group
Group type: EXPERIMENTAL
Intervention: Social-cognitive intervention to promote volunteering
Number of subjects: 360
Study 30678635 — intervention group
Group type: COMPARATOR
Intervention: Active control intervention targeting physical activity
Number of subjects: 360
Study 28698335 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard antiepileptic drugs
Number of subjects: 0
Study 28698335 — intervention group
Group type: EXPERIMENTAL
Intervention: New antiepileptic drugs
Number of subjects: 0
Study 26467303 — intervention group
Group type: EXPERIMENTAL
Intervention: Common Elements Treatment Approach (CETA)
Number of subjects: 378
Study 26467303 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 378
Study 26467303 — intervention group
Group type: COMPARATOR
Intervention: Wait-list Control (WLC) for CETA
Number of subjects: 378
Study 26467303 — intervention group
Group type: COMPARATOR
Intervention: Wait-list Control (WLC) for CPT
Number of subjects: 378
Study 23354911 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic treatment (5 treatment sessions)
Number of subjects: 20
Study 22093930 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee arthroscopic synovectomy plus DMARD
Number of subjects: 97
Study 22093930 — intervention group
Group type: COMPARATOR
Intervention: DMARD
Number of subjects: 97
Study 19288305 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Human Dissector (VHD) software
Number of subjects: 89
Study 19288305 — intervention group
Group type: COMPARATOR
Intervention: Prosections and models in the dissecting room (DR)
Number of subjects: 89
Study 16788707 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (300 mg/day)
Number of subjects: 37
Study 16788707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 12182509 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education about the nature, causes, prevalence and treatment of depression
Number of subjects: 70
Study 12182509 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no educational intervention)
Number of subjects: 70
Study 10333193 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme supplementation (9 sachets per day containing lipase 36,000, amylase 27,000, protease 2400 FIP) for 14 days
Number of subjects: 52
Study 10333193 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical-looking sachets) for 14 days
Number of subjects: 52
Study 10333193 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme supplementation
Number of subjects: 52
Study 8542859 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 60 mg
Number of subjects: 60
Study 8542859 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg
Number of subjects: 60
Study 8542859 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control) 3 mL
Number of subjects: 60
Study 2013674 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mol/L fraction
Number of subjects: 0
Study 2013674 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mol/L fraction
Number of subjects: 0
Study 2013674 — intervention group
Group type: EXPERIMENTAL
Intervention: Distilled water fraction
Number of subjects: 0
Study 2013674 — intervention group
Group type: EXPERIMENTAL
Intervention: Other fractions
Number of subjects: 0
Study 2013674 — intervention group
Group type: EXPERIMENTAL
Intervention: H2O fraction
Number of subjects: 0
Study 2013674 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mol/L and H2O fractions
Number of subjects: 0
Study 7032226 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bedtime dose of chlorpromazine (300 mg)
Number of subjects: 80
Study 7032226 — intervention group
Group type: COMPARATOR
Intervention: Divided doses of chlorpromazine (100 mg, thrice daily)
Number of subjects: 80
Study 31508608 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumentation with master apical files (MAF) 50/0.05
Number of subjects: 100
Study 31508608 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumentation with master apical files (MAF) 55/0.05
Number of subjects: 100
Study 31508608 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumentation with master apical files (MAF) 60/0.05
Number of subjects: 100
Study 31508608 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumentation with master apical files (MAF) 40/0.15
Number of subjects: 100
Study 31508608 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumentation with master apical files (MAF) 45/0.15
Number of subjects: 100
Study 31508608 — intervention group
Group type: COMPARATOR
Intervention: Control group (uninstrumented roots)
Number of subjects: 100
Study 28371811 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Brief Intervention (BI) lasting 15-30 min plus general health education, n = 118
Number of subjects: 239
Study 28371811 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only general health education, n = 121
Number of subjects: 239
Study 28371811 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Brief Intervention (BI)
Number of subjects: 239
Study 25673976 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary argan oil
Number of subjects: 60
Study 25673976 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosmetic argan oil application
Number of subjects: 60
Study 25673976 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 60
Study 23958332 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Social Behavior and Network Therapy (B‐SBNT)
Number of subjects: 120
Study 23958332 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Goal Setting (PGS)
Number of subjects: 120
Study 23958332 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 120
Study 23958332 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐SBNT and PGS (plus routine treatment)
Number of subjects: 120
Study 23958332 — intervention group
Group type: EXPERIMENTAL
Intervention: Family members of patients
Number of subjects: 120
Study 21199584 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-in consent
Number of subjects: 1129
Study 21199584 — intervention group
Group type: COMPARATOR
Intervention: Opt-out consent
Number of subjects: 1129
Study 18289903 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone therapy (GH) starting dose of 0.1mg/day, adjusted to maintain IGF‐I levels between 0 and 2 SDS for gender and age.
Number of subjects: 71
Study 18289903 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GH therapy)
Number of subjects: 71
Study 17294991 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural analgesia (CSEA)
Number of subjects: 50
Study 17294991 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia (EA)
Number of subjects: 50
Study 14693710 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal glucose tolerance (NGT) subjects (nonconverters)
Number of subjects: 2279
Study 14693710 — intervention group
Group type: COMPARATOR
Intervention: Normal glucose tolerance (NGT) subjects who converted to diabetes
Number of subjects: 2279
Study 14693710 — intervention group
Group type: COMPARATOR
Intervention: Impaired glucose tolerance subjects who converted to diabetes
Number of subjects: 2279
Study 14693710 — intervention group
Group type: EXPERIMENTAL
Intervention: Converters (both NGT and impaired glucose tolerance)
Number of subjects: 2279
Study 14693710 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in 2-h postglucose insulin levels
Number of subjects: 2279
Study 10079412 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence in situ hybridization (FISH) using chromosome probes 13, 16, 18, 21, 22, X, and Y
Number of subjects: 33
Study 10079412 — intervention group
Group type: EXPERIMENTAL
Intervention: FISH using selected chromosome probes
Number of subjects: 33
Study 7739943 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (nitrous oxide, isoflurane 0.5‐1.0%)
Number of subjects: 22
Study 7739943 — intervention group
Group type: COMPARATOR
Intervention: Balanced anesthesia (nitrous oxide, fentanyl, midazolam)
Number of subjects: 22
Study 7739943 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Isoflurane and Balanced anesthesia)
Number of subjects: 22
Study 7739943 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 22